MicroRNA determinants of the balance between effector and regulatory T cells in...
MicroRNA determinants of the balance between effector and regulatory T cells in vivo
T lymphocytes display potent pro- or anti-inflammatory properties, which typically associate with distinct effector (Teff) versus regulatory (Treg) cell subsets. Based on published and our preliminary data showing a major impact o...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BFU2008-01651
SEÑALIZACION INTRACELULAR Y ESTRUCTURA SUBNUCLEAR EN LA RECO...
36K€
Cerrado
SAF2011-22463
MECANISMOS MODULADORES DE LA DIFERENCIACION Y ACTIVIDAD FUNC...
200K€
Cerrado
PID2021-128720NB-I00
MECANISMOS DE SEÑALIZACION PARA EL CONTROL DE LA TRANSCRIPCI...
157K€
Cerrado
PID2019-104703GB-I00
IDENTIDAD, TOPOLOGIA Y GEOMETRIA DE LOS DOMINIOS DE SEÑALIZA...
127K€
Cerrado
PID2021-125757OB-I00
INTERACCIONES GENICAS Y PROTEICAS DE CD69 Y SUS REGIONES GEN...
157K€
Cerrado
SAF2016-80803-R
ANALISIS DE UNA NUEVA FUNCION DE P21 COMO SUPPRESOR SELECTIV...
145K€
Cerrado
Información proyecto DevoTed_miR
Duración del proyecto: 68 meses
Fecha Inicio: 2015-06-23
Fecha Fin: 2021-02-28
Descripción del proyecto
T lymphocytes display potent pro- or anti-inflammatory properties, which typically associate with distinct effector (Teff) versus regulatory (Treg) cell subsets. Based on published and our preliminary data showing a major impact of microRNAs on T cell differentiation and (auto)immune pathology, my proposal aims to dissect the miRNA networks that control the balance between Teff and Treg subsets in vivo, in various experimental models of infection and autoimmunity.
We will focus on three critical mediators of T cell functions: interferon-gamma (IFN-g) and interleukin-17A (IL-17), highly pro-inflammatory Teff cytokines; and Foxp3, the transcription factor that confers Treg suppressive properties. To track the activity of these key genes, we will generate a new Ifng/ Il17/ Foxp3 triple reporter mouse, from which we will isolate Teff and Treg subsets to determine their genome-wide miRNA profiles and specific signatures in vivo. We will investigate both natural (thymic-derived and present in naïve mice) and induced (in the periphery upon challenge) Teff and Treg subsets, as they make distinct contributions to the immune response. We will identify miRNAs selectively expressed in Teff (Ifng+ or Il17+) versus Treg (Foxp3+) subsets of various lineages (CD4+, CD8+, gamma-delta or NKT) in each in vivo model; assess whether they are induced during thymic development or upon peripheral activation; and determine the robustness of subset-specific miRNA profiles across various in vivo challenges.
We will then use loss- and gain-of-function strategies to define the individual miRNAs that impact Teff or Treg differentiation and disease pathogenesis; dissect the external cues and intracellular mechanisms that regulate miRNA expression; and identify the mRNA networks controlled by key miRNAs in Teff and Treg differentiation. I expect this project to provide major conceptual and experimental advances towards manipulating miRNAs either to boost immunity or to treat autoimmunity.